Development

Webinar Date/Time: Tue, May 14, 2024 1:00 PM EDT

Webinar Date/Time: Tue, Jun 11, 2024 10:00 AM EDT

This article represents a comprehensive exploration about biopharmaceutical excipients, exploring their multifaceted classification, active role in drug formulation processes, inherent challenges, and upcoming advancements poised to revolutionize the drug formulation and its efficacy for patient welfare.

Webinar Date/Time: Tue, May 21, 2024 11:00 AM EDT

Webinar Date/Time: Thu, May 16, 2024 11:00 AM EDT

The collaboration will focus on differentiated cancer vaccine candidates in hematological and solid tumor indications to treat unmet medical needs.

In back-to-back deals, Charles River will offer plasmid DNA manufacturing services for a gene therapy under development by Axovia Therapeutics and for a lead candidate being developed by Ship of Theseus.

In a $1.8 billion transaction, Genmab will gain three clinical-stage next-generation ADC candidates with its acquisition of ProfoundBio.

Innovation in this space depends on strategizing for GMP compliance and market access.

Experts believe it is likely cancer cells are more common in the body than previously thought, but typically caught early and removed in the body’s cancer-immune cycle. When the system is in good working order (and protecting us), dead cancer cells release neoantigens.

J&J’s nipocalimab is in development for reducing the risk of FNAIT in alloimmunized pregnant adults, a rare disease that may risk the life of the fetus or newborn.

AstraZeneca notes that Ultomiris is the first and only long-acting C5 complement inhibitor that offers NMOSD patients the potential to live without relapsing.

AbbVie’s acquisition of Landos includes a lead asset that boosts its portfolio in autoimmune and inflammatory diseases, while the ADC, ELAHERE, gets full FDA approval.

Webinar Date/Time: Thu, Thu, Apr 18, 2024 11:00 AM EDT

Webinar Date/Time: Thu, Apr 25, 2024 11:00 AM EDT

Webinar Date/Time: Wed, May 8, 2024 11:00 AM EDT

ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection

Under a new agreement, Chime Biologics will manufacture Domain Therapeutics’ antibody cancer immunotherapy candidate, DT-7012.

EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Despite a growing number of biosimilar approvals, market uptake remains a challenge.

Proprietary cell lines offer opportunities for achieving high AAV titers.

CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.